The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Ception

Cephalon-Ception’s Canadian Connection: Great News for Lumira Capital and McMaster in $250 million Option Deal

At the beginning of 2009, when Ception Therapeutics was working on mid-stage trials of its lead compound, it struck an option deal with Cephalon (NASDAQ: CEPH): $100 million up-front, and an option to acquire the rest of Ception for $250 million more. 

This week, Cephalon exercised the option after taking a look at Phase II results for Cinquil (reslizumab), a novel biologic that could potentially be used to treat asthma and Pediatric Eosinophilic Esophagitis. 

Among many other beneficiaries, foremost among them hopefully being patients, this deal is great news for Canadian-based VC firm Lumira Capital*, which co-led the deal, and for McMaster University, which did some of the clinical work on the drug. 

According to FierceBiotech, the $350 million paid so far is not the end of the story either, as Ception shareholders will benefit from future clinical and regulatory milestones.

Bookmark and Share

* occasional contributors to this publication.

Canadian Life Sciences VCs Lead the Realization Parade

Liquidity Shrivels Up For VCs in First Quarter” was the banner screaming across the wire services earlier this week. While true, what was lost in the subtext were a few important observations for Canadian VCs, particularly those focused on life sciences:

Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 129 other followers